Takeda Pharmaceutical Co. Ltd. ADR (TAK): Price and Financial Metrics

Takeda Pharmaceutical Co. Ltd. ADR (TAK): $13.18

0.19 (-1.42%)

POWR Rating

Component Grades








TAK Price/Volume Stats

Current price $13.18 52-week high $17.11
Prev. close $13.37 52-week low $13.17
Day low $13.17 Volume 1,788,800
Day high $13.35 Avg. volume 1,861,449
50-day MA $14.25 Dividend yield 3.91%
200-day MA $14.68 Market Cap 41.71B

TAK Stock Price Chart Interactive Chart >

Takeda Pharmaceutical Co. Ltd. ADR (TAK) Company Bio

The Takeda Pharmaceutical Company Limited (武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha[takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with Shire). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neurosciencegastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-kuOsaka, and it has an office in NihonbashiChuoTokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. (Source:Wikipedia)

TAK Latest News Stream

Event/Time News Detail
Loading, please wait...

TAK Latest Social Stream

Loading social stream, please wait...

View Full TAK Social Stream

Latest TAK News From Around the Web

Below are the latest news stories about TAKEDA PHARMACEUTICAL CO LTD that investors may wish to consider to help them evaluate TAK as an investment opportunity.

One Ultra-Cheap High-Yield Dividend Stock to Buy

Now may be a good time for dividend investors to consider loading up on this stock.

Yahoo | December 22, 2023

Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies

OSAKA, Japan & CAMBRIDGE, Massachusetts, December 21, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that LIVTENCITY® (maribavir) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarne

Yahoo | December 21, 2023

Takeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA®, Treatment for Rare form of Emphysema

Takeda Canada Inc. (Takeda) has entered into a contract with Canadian Blood Services (CBS) for GLASSIA® (alpha-1 proteinase inhibitor) resulting from CBS's request for proposal for hereditary deficiency of Alpha-1 Antitrypsin Deficiency (Alpha-1). Glassia has been approved to be listed on the CBS Plasma Protein and Related Products (PPRP) formulary with specific criteria for reimbursement. This marks Takeda's entry into the Alpha-1 community in Canada, building on the company's commitment to dev

Yahoo | December 20, 2023

13 Most Promising Healthcare Stocks According to Analysts

In this article, we discuss the 13 most promising healthcare stocks according to analysts. To skip the detailed overview of the healthcare sector, go directly to the 5 Most Promising Healthcare Stocks According to Analysts. The healthcare industry landscape is changing. While the COVID-19 pandemic was one of the most significant events that led to […]

Yahoo | December 19, 2023

Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

OSAKA, Japan & CAMBRIDGE, Mass., December 15, 2023--The CHMP has recommended the approval of Takeda's HYQVIA in patients with CIDP as maintenance therapy after stabilization with IVIG.

Yahoo | December 15, 2023

Read More 'TAK' Stories Here

TAK Price Returns

1-mo -8.91%
3-mo -11.31%
6-mo -9.29%
1-year -19.67%
3-year -18.26%
5-year -20.25%
YTD -7.64%
2023 -7.00%
2022 16.87%
2021 -23.58%
2020 -5.97%
2019 19.31%

TAK Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full TAK Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!